Tigress Financial raised the firm’s price target on Medline (MDLN) to $62 from $60 and keeps a Buy rating on the shares, arguing that the company’s the ongoing transition from a traditional medical distributor to “a data-rich, AI-enabled supply chain partner” creates “near-term noise,” but “a long-term buying opportunity.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline price target lowered to $42 from $48 at Deutsche Bank
- Medline price target lowered to $54 from $56 at Bernstein
- Medline price target lowered to $55 from $60 at Citi
- Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
- Medline reports Q1 adjusted EPS 33c, consensus 29c